The specialized, oxygen free handling a strict anaerobe like this bacterium requires.
Oak Ridge National LaboratoryCC BY 2.0
Illustrative, an unrelated lab, not the Caelus dossier itself.
A Regulator Just Cleared a Gut Bacterium Whose Only Job Is Making Butyrate
Almost every probiotic capsule on a shelf right now is some strain of Lactobacillus or Bifidobacterium, organisms picked in large part because they are easy to grow in the presence of air and have been in fermented food for millennia. A regulator just cleared something built differently, and I think it is worth understanding why before it starts showing up in ingredient lists.
- On July 1, 2026, EFSA's scientific panel adopted a positive safety opinion on freeze dried Anaerobutyricum soehngenii CH106, a strict anaerobe taken directly from the human colon, the first live gut native commensal of its kind to clear the EU Novel Food safety review.
- Unlike almost every probiotic on a shelf today, which is a Lactobacillus or Bifidobacterium, this organism's actual job is converting lactate and acetate into butyrate, the compound that fuels the cells lining your colon.
- This is a safety opinion, not an approval and not an efficacy finding. The European Commission has not authorized it, and EFSA made no determination that it does anything beneficial.
- Read next to a separate recent finding that probiotic use rose 287 percent in adults while fiber intake fell, this is the same target, butyrate production, approached from two very different directions, one a regulator clearing a bacterium built to make it directly, the other fiber, which buys it far more cheaply and almost nobody eats enough of.
A bacterium chosen for what it makes, not what it survives
On July 1, 2026, the European Food Safety Authority's scientific panel adopted a positive safety opinion on freeze dried Anaerobutyricum soehngenii CH106, developed by Caelus Pharmaceuticals in the Netherlands. This organism is a strict anaerobe, meaning it cannot tolerate oxygen the way a typical shelf stable probiotic strain can, and it was taken directly from the human colon rather than isolated from yogurt or another fermented food. It is the first live, gut native commensal of this type to clear the EU's Novel Food safety review, a process the company's application entered back in July 2022, four years before this opinion.
What makes this organism interesting is not survivability, it is metabolism. Anaerobutyricum soehngenii converts lactate and acetate, both already present in the gut, into butyrate, the short chain fatty acid that is the primary fuel source for the cells lining your colon and the compound most consistently tied to gut barrier integrity and immune signaling. Rather than adding a generic "good bacterium" and hoping it happens to ferment something useful, this is a targeted attempt to install a specific metabolic step, a lactate and acetate sink that yields butyrate, directly into a gut where that step may be underperforming.
What EFSA actually concluded, and what it did not
Read directly from the adopted opinion, EFSA's panel concluded the organism is safe for the general adult population, excluding pregnant and lactating women, at up to 2.0 times 10 to the 9th active fluorescent units per day. Identity, production process, composition, stability, and specification were all judged sufficient and not raising safety concerns, with no genotoxicity concerns identified. That dose is specified in AFU, active fluorescent units, a flow cytometry viability measurement, not CFU, colony forming units, the plate count method every other probiotic on a shelf uses. Those two units do not convert into each other, so as AFU specified products start appearing next to CFU labeled ones, reading the fine print will actually matter.
Honest caveat
This is a safety opinion, not an authorization and not an efficacy finding, and that distinction has to stay explicit. The European Commission has not yet made an authorization decision, and EFSA assessed no clinical benefit whatsoever, no efficacy trial for this specific strain, CH106, was retrieved or assessed here. Earlier academic work on Anaerobutyricum soehngenii in metabolic health exists but was not verified in this brief and is not being cited as support. This is also an EU regulatory process only, there is no US regulatory status, no US product exists, and this is a "what is coming" story, not a "what to buy" one. The applicant, Caelus Pharmaceuticals, is an interested party in the underlying dossier, which is true of essentially every novel food application, and it is EFSA's independent assessment of that dossier that this brief is actually reporting on. Pregnant and lactating women, along with infants and young children, were explicitly excluded from the safety conclusion.
What this means for you
You cannot buy this specific bacterium yet, and if a European Commission authorization eventually arrives, that will be a different, separate event worth watching. What is genuinely useful right now is the frame it puts around a habit you might already have. If you take a probiotic hoping it supports gut health, the mechanism most people are actually reaching for is butyrate production, and fiber already buys you that outcome far more cheaply than any capsule, generic or novel, ever will. A national survey published just one day before this opinion resurfaced in trade coverage found probiotic supplement use rising 287 percent in US adults over 14 years while fiber intake actually fell over the same period. A regulator clearing a bacterium whose entire purpose is making butyrate is a genuinely interesting scientific development. It is not a substitute for the food your existing gut bacteria are already capable of turning into the same compound, if you feed them.
Primary sources
Common questions
Is this new bacterium approved for sale yet?
Not yet. EFSA issued a positive safety opinion, which means its scientists concluded the organism is safe at the proposed dose. That is one input to a separate European Commission authorization decision, which has not been issued. It is also an EU process only, so there is no US regulatory status and no US product on shelves.
Does this mean the bacterium actually improves gut health?
EFSA assessed safety only, and made no determination that it does anything beneficial. No clinical benefit trial for this specific strain, CH106, was retrieved or assessed in this brief. The interesting part is what it is designed to do, convert lactate and acetate into butyrate, not proof that doing so in a supplement produces a measurable health outcome yet.
What is the difference between AFU and CFU on a probiotic label?
CFU, colony forming units, is the plate count method almost every probiotic on the shelf uses. AFU, active fluorescent units, is a flow cytometry viability count, a different measurement method entirely. This bacterium's proposed dose is specified in AFU, 2 billion per day, and that number cannot be converted to or compared directly against a CFU figure on another label.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.